Senores Pharma: No Deviation in Preferential Issue Fund Use

Senores Pharmaceuticals Limited has submitted its quarterly statement of deviation or variation in the utilization of funds raised through a preferential issue of 11,70,000 convertible equity warrants. The company raised Rs. 95,00,40,000 (Rs. 95.00 Crore) on March 28, 2026. For the quarter ended September 30, 2026, the company confirms there has been no deviation from the stated objects for the utilization of these funds. The statement was reviewed by the Audit Committee and taken on record by the Board of Directors. The total utilized amount for the quarter was Rs. 16,91,10,000 (Rs. 16.91 Crore) across various objectives including working capital, product development, subsidiary investment, and general corporate purposes, with no deviation reported.